Healthcare Professionals

Cancer therapies vary in their effectiveness and in most instances, standard treatment regimens are unsuccessful in a majority of patients — it has been estimated that overall objective response rates to cancer therapies is only 25 percent. And for some cancers, it may be even lower.

A retrospective analysis of 43 patients with advanced NSCLC who had received third- or fourth-line chemotherapy after two prior regimens that included platinum and docetaxel given concurrently or sequentially.1

NCCN = National Comprehensive Cancer Network; NSCLC = non-small-cell lung cancer.

Use your patient’s own tumor to help individualize your treatment approach.

Champions TumorGraft® patient-derived xenograft (PDX) models are in vivo models that deliver tumor-specific data to help you select the optimal treatment regimen for your patient.

Champions Oncology is accreditied with The Joint Commission, certified by the Clinical Laboratory Improvement Amendment (“CLIA”) and has received approval from state departments of health, including the New York State Department of Health.

Tumors that have been tested successfully using PDX models include cancers of the colon, pancreas, stomach, esophagus, lung and breast, as well as sarcomas and others. Anticancer therapies should be analyzed for each particular patient, with all peculiarities concerned.

Learn How the Personalized TumorGraft Process Works >

Champions Oncology - Specializing in | Personalized Cancer Therapy | Translational Oncology Solutions | Oncology drug development | Oncology drug discovery | Translational oncology | Translation oncology research | Predictive oncology | Patient-derived xenograft model | Tumorgrafts | Alternative/new cancer treatment | Anticancer therapies | Personalized cancer treatment | Personalized cancer therapy | Personalized oncology